Recursion Pharmaceuticals (RXRX) Asset Writedowns and Impairment (2022 - 2025)

Recursion Pharmaceuticals' Asset Writedowns and Impairment history runs 4 years deep, the most recent figure standing at $6.0 million for Q1 2025.

• Quarterly Asset Writedowns and Impairment rose 5414.81% year-over-year to $6.0 million in Q1 2025, while the trailing twelve-month figure through Dec 2025 was $6.0 million (up 5414.81% YoY) and the FY2025 annual result came in at $6.0 million, up 5414.81% from the prior year.
• Asset Writedowns and Impairment was $6.0 million for Q1 2025 at Recursion Pharmaceuticals, up from $108000.0 in the prior quarter.
• Across five years, Asset Writedowns and Impairment topped out at $6.0 million in Q1 2025 and bottomed at $19000.0 in Q3 2023.
• A 4-year average of $2.0 million and a median of $1.2 million in 2023 frame the typical range for Asset Writedowns and Impairment.
• Annual changes were most pronounced in 2024 — Asset Writedowns and Impairment tumbled 90.76% — and 2025, when it soared 5414.81%.
• Recursion Pharmaceuticals' Asset Writedowns and Impairment stood at $2.8 million in 2022, then tumbled by 99.32% to $19000.0 in 2023, then jumped by 468.42% to $108000.0 in 2024, then jumped by 5414.81% to $6.0 million in 2025.
• Business Quant data shows RXRX's Asset Writedowns and Impairment at $6.0 million in Q1 2025, $108000.0 in Q1 2024, and $19000.0 in Q3 2023.